Inhibrx Biosciences, Inc. (INBX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は La Jolla, CA, アメリカ. 現CEOは Mark Paul Lappe.
INBX を有する IPO日 2024-06-04, 156 名の正社員, に上場 NASDAQ Global Market, 時価総額 $1.22B.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
